Suppressive effect of astaxanthin on retinal injury induced by elevated intraocular pressure

Regulatory Toxicology and Pharmacology

Volumn 58, Issue 1, 2010, Pages 121-130

  Cort, Aysegul ^a   Ozturk, Nihal ^a   Akpinar, Deniz ^a   Unal, Mustafa ^a   Yucel, Gultekin ^a   Ciftcioglu, Akif ^a   Yargicoglu, Piraye ^a   Aslan, Mutay ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Astaxanthin; Intraocular pressure; Visual evoked potentials

Indexed keywords

ASTAXANTHIN; CARBONYL DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; OLIVE OIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; EVOKED VISUAL RESPONSE; EYE PROTECTION; IMMUNOHISTOCHEMISTRY; INTRAOCULAR HYPERTENSION; LATENT PERIOD; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA CELL; RETINA INJURY; TREATMENT DURATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; EYE INJURIES; GLUTATHIONE; GLUTATHIONE DISULFIDE; LIPID PEROXIDATION; MALE; NITRIC OXIDE SYNTHASE TYPE II; OCULAR HYPERTENSION; PROTECTIVE AGENTS; PROTEIN CARBONYLATION; RATS; RATS, WISTAR; RETINA; XANTHOPHYLLS;

RATTUS;

EID: 77955919148     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.05.001     Document Type: Article

References (70)

1. Akpinar D., Yargicoglu P., Derin N., Aslan M., Agar A. Effect of aminoguanidine on visual evoked potentials (VEPs), antioxidant status and lipid peroxidation in rats exposed to chronic restraint stress. Brain Res. 2007, 1186:87-94.
2. Aslan M., Cort A., Yucel I. Oxidative and nitrative stress markers in glaucoma. Free Radic. Biol. Med. 2008, 45:367-376.
3. Aslan M., Yucel I., Ciftcioglu A., Savaş B., Akar Y., Yucel G., Sanlioglu S. Corneal protein nitration in experimental uveitis. Exp. Biol. Med. (Maywood) 2007, 232:1308-1313.
4. Aslan M., Yücel I., Akar Y., Yücel G., Ciftçioĝlu M.A., Sanlioglu S. Nitrotyrosine formation and apoptosis in rat models of ocular injury. Free Radic Res. 2006, 40:147-153.
5. Bazan N.G., Marcheselli V.L., Cole-Edwards K. Brain response to injury and neurodegeneration: endogenous neuroprotective signaling. Ann. NY Acad. Sci. 2005, 1053:137-147.
6. Cabrera C.L., Wagner L.A., Schork M.A., Bohr D.F., Cohan B.E. Intraocular pressure measurement in the conscious rat. Acta Ophthalmol. Scand. 1999, 77:33-36.
7. Clark R.M., Yao L., She L., Furr H.C. A comparison of lycopene and astaxanthin absorption from corn oil and olive oil emulsions. Lipids 2000, 35:803-806.
8. Curek G.D., Cort A., Yucel G., Demir N., Ozturk S., Elpek G.O., Savas B., Aslan M. Effect of astaxanthin on hepatocellular injury following ischemia/reperfusion. Toxicology 2010, 267:147-153.
9. Coleman A.L. Glaucoma. Lancet 1999, 354:1803-1810.
10. De La Paz M.A., Epstein D.L. Effect of age on superoxide dismutase activity of human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 1996, 37:1849-1853.
11. Derin N., Akpinar D., Yargicoglu P., Agar A., Aslan M. Effect of alpha-lipoic acid on visual evoked potentials in rats exposed to sulfite. Neurotoxicol. Teratol. 2009, 31:34-39.
12. Fechtner R.D., Weinreb R.N. Mechanisms of optic nerve damage in primary open angle glaucoma. Surv. Ophthalmol. 1994, 39:23-42.
13. Gaasterland D., Tanishima T., Kuwabara T. Axoplasmic flow during chronic experimental glaucoma. 1. Light and electron microscopic studies of the monkey optic nervehead during development of glaucomatous cupping. Invest. Ophthalmol. Vis. Sci. 1978, 17:838-846.
14. Gherghel D., Griffiths H.R., Hilton E.J., Cunliffe I.A., Hosking S.L. Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci. 2005, 46:877-883.
15. Gottanka J., Johnson D.H., Martus P., Lütjen-Drecoll E. Severity of optic nerve damage in eyes with POAG is correlated with changes in the trabecular meshwork. J. Glaucoma. 1997, 6:123-132.
16. Graham S.L., Klistorner A. Electrophysiology: a review of signal origins and applications to investigating glaucoma. Aust. NZ J. Ophthalmol. 1998, 26:71-85.
17. Hall A., Karplus P.A., Poole L.B. Typical 2-Cys peroxiredoxins - structures, mechanisms and functions. FEBS J. 2009, 276:2469-2477.
18. Herr D.W., King D., Barone S., Crofton K.M. Alterations in flash evoked potentials (FEPs) in rats produced by 3,3'-iminodipropionitrile (IDPN). Neurotoxicol. Teratol. 1995, 17:645-656.
19. Howe J.W., Mitchell K.W. Visual evoked potential changes in chronic glaucoma and ocular hypertension. Trans. Ophthalmol. Soc. UK 1986, 105(Pt 4):457-462.
20. Ishida K., Yamamoto T., Kitazawa Y. Clinical factors associated with progression of normal-tension glaucoma. J. Glaucoma. 1998, 7:372-377.
21. Izzotti A. DNA damage and alterations of gene expression in chronic-degenerative diseases. Acta Biochim. Pol. 2003, 50:145-154.
22. JECFA, 1996. Toxicological evaluation of certain food additives and contaminants in food, WHO Food Additive Series, vol. 35, World Health Organization, Geneva.
23. Jewell C., O'Brien N.M. Effect of dietary supplementation with carotenoids on xenobiotic metabolizing enzymes in the liver, lung, kidney and small intestine of the rat. Br. J. Nutr. 1999, 81:235-242.
24. Jia L., Cepurna W.O., Johnson E.C., Morrison J.C. Effect of general anesthetics on IOP in rats with experimental aqueous outflow obstruction. Invest. Ophthalmol. Vis. Sci. 2000, 41:3415-3419.
25. Johnson E.J. The role of carotenoids in human health. Nutr. Clin. Care. 2002, 5:56-65.
26. Jonas J.B., Budde W.M., Lang P. Neuroretinal rim width ratios in morphological glaucoma diagnosis. Br. J. Ophthalmol. 1998, 82:1366-1371.
27. Kang J.H., Pasquale L.R., Willett W., Rosner B., Egan K.M., Faberowski N., Hankinson S.E. Antioxidant intake and primary open-angle glaucoma: a prospective study. Am. J. Epidemiol. 2003, 158:337-346.
28. Ko M.L., Peng P.H., Ma M.C., Ritch R., Chen C.F. Dynamic changes in reactive oxygen species and antioxidant levels in retinas in experimental glaucoma. Free Radic. Biol. Med. 2005, 39:365-373.
29. Krinsky N.I., Johnson E.J. Carotenoid actions and their relation to health and disease. Mol. Aspects Med. 2005, 26:459-516.
30. Krinsky N.I., Landrum J.T., Bone R.A. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Annu. Rev. Nutr. 2003, 23:171-201.
31. Kurashige M., Okimasu E., Inoue M., Utsumi K. Inhibition of oxidative injury of biological membranes by astaxanthin. Physiol. Chem. Phys. Med. NMR 1990, 22:27-38.
32. Landrum J.T., Bone R.A., Moore L.L., Gomez C.M. Analysis of zeaxanthin distribution within individual human retinas. Methods Enzymol. 1999, 299:457-467.
33. Lehman D.M., Harrison J.M. Flash visual evoked potentials in the hypomyelinated mutant mouse shiverer. Doc. Ophthalmol. 2002, 104:83-95.
34. Liu B., Neufeld A.H. Expression of nitric oxide synthase-2 (NOS-2) in reactive astrocytes of the human glaucomatous optic nerve head. Glia 2000, 30:178-186.
35. Miyamoto N., Izumi H., Miyamoto R., Kubota T., Tawara A., Sasaguri Y., Kohno K. Nipradilol and timolol induce Foxo3a and peroxiredoxin 2 expression and protect trabecular meshwork cells from oxidative stress. Invest. Ophthalmol. Vis. Sci. 2009, 50:2777-2784.
36. Naguib Y.M. Antioxidant activities of astaxanthin and related carotenoids. J. Agric. Food. Chem. 2000, 48:1150-1154.
37. Nakajima Y., Inokuchi Y., Shimazawa M., Otsubo K., Ishibashi T., Hara H. Astaxanthin, a dietary carotenoid, protects retinal cells against oxidative stress in-vitro and in mice in-vivo. J. Phar. Pharmacol. 2008, 60:1365-1374.
38. Nemesure B., Wu S.Y., Hennis A., Leske M.C. Factors related to the 4-year risk of high intraocular pressure: the Barbados Eye Studies. Arch. Ophthalmol. 2003, 121:856-862. Barbados Eye Studies Group.
39. Neufeld A.H., Sawada A., Becker B. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc. Natl. Acad. Sci. USA 1999, 96:9944-9948.
40. Nieminen T., Lehtimäki T., Mäenpää J., Ropo A., Uusitalo H., Kähönen M. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand. J. Clin. Lab. Invest. 2007, 67:237-245.
41. Ohgami K., Shiratori K., Kotake S., Nishida T., Mizuki N., Yazawa K., Ohno S. Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Invest. Ophthalmol. Vis. Sci. 2003, 44:2694-2701.
42. Palozza P., Krinsky N.I. Astaxanthin and canthaxanthin are potent antioxidants in a membrane model. Arch. Biochem. Biophys. 1992, 297:291-295.
43. Petri D., Lundebye A.K. Tissue distribution of astaxanthin in rats following exposure to graded levels in the feed. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2007, 145:202-209.
44. Quigley H.A. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 1996, 80:389-393.
45. Quigley H.A., Addicks E.M. Chronic experimental glaucoma in primates. II. Effect of extended intraocular pressure elevation on optic nerve head and axonal transport. Invest. Ophthalmol. Vis. Sci. 1980, 19:137-152.
46. Roberts R.L., Green J., Lewis B. Lutein and zeaxanthin in eye and skin health. Clin. Dermatol. 2009, 27:195-201.
47. Reznick A.Z., Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol. 1994, 233:357-363.
48. Saccà S.C., Izzotti A., Rossi P., Traverso C. Glaucomatous outflow pathway and oxidative stress. Exp. Eye Res. 2007, 84:389-399.
49. Saccà S.C., Pascotto A., Camicione P., Capris P., Izzotti A. Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Arch. Ophthalmol. 2005, 123:458-463.
50. Salmon, J.F., Glaucoma. Riordan-Eva, P., Whitcher, J.P., Asbury, T. (Eds.), 2008. Vaughan & Asbury's General Ophthalmology, 17th ed. (Chapter 11). McGraw-Hill, New York, pp. p212-p222.
51. Sawada A., Neufeld A.H. Confirmation of the rat model of chronic, moderately elevated intraocular pressure. Exp. Eye Res. 1999, 69:525-531.
52. Schroeder C.E., Tenke C.E., Givre S.J., Arezzo J.C., Vaughan H.G. Striate cortical contribution to the surface-recorded pattern-reversal VEP in the alert monkey. Vision Res. 1991, 31:1143-1157.
53. Shacter E. Protein oxidative damage. Methods Enzymol. 2000, 319:428-436.
54. Shareef S., Sawada A., Neufeld A.H. Isoforms of nitric oxide synthase in the optic nerves of rat eyes with chronic moderately elevated intraocular pressure. Invest. Ophthalmol. Vis. Sci. 1999, 40:2884-2891.
55. Shareef S.R., Garcia-Valenzuela E., Salierno A., Walsh J., Sharma S.C. Chronic ocular hypertension following episcleral venous occlusion in rats. Exp. Eye Res. 1995, 61:379-382.
56. Shibata A., Kiba Y., Akati N., Fukuzawa K., Terada H. Molecular characteristics of astaxanthin and beta-carotene in the phospholipid monolayer and their distributions in the phospholipid bilayer. Chem. Phys. Lipids 2001, 113:11-22.
57. Silver S., Sohmer H., Kapitulnik J. Visual evoked potential abnormalities in jaundiced Gunn rats treated with sulfadimethoxine. Pediatr. Res. 1995, 38:258-261.
58. Stadtman E.R., Oliver C.N. Metal-catalyzed oxidation of proteins. Physiological consequences. J. Biol. Chem. 1991, 266:2005-2008.
59. Stahl W., Sies H. Bioactivity and protective effects of natural carotenoids. Biochim. Biophys. Acta 2005, 1740:101-107.
60. Sucher N.J., Lipton S.A., Dreyer E.B. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res. 1997, 37:3483-3493.
61. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog. Retin. Eye Res. 2006, 25:490-513.
62. Tezel G., Yang X. Caspase-independent component of retinal ganglion cell death. Invest. Ophthalmol. Vis. Sci. 2004, 45:4049-4059.
63. Tezel G., Yang X., Cai J. Proteomic identification of oxidatively modified retinal proteins in a chronic pressure-induced rat model of glaucoma. Invest. Ophthalmol. Vis. Sci. 2005, 46:3177-3187.
64. Towle V.L., Moskowitz A., Sokol S., Schwartz B. The visual evoked potential in glaucoma and ocular hypertension: effects of check size, field size, and stimulation rate. Invest. Ophthalmol. Vis. Sci. 1983, 24:175-183.
65. Tso, M.O.M., Lam, T.T., 1996. Method of Retarding and Ameliorating Central Nervous System and Eye Damage. U.S. Patent #5527533.
66. Wasowicz W., Nève J., Peretz A. Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: importance of extraction pH and influence of sample preservation and storage. Clin. Chem. 1993, 39:2522-2526.
67. Yan D.B., Coloma F.M., Metheetrairut A., Trope G.E., Heathcote J.G., Ethier C.R. Deformation of the lamina cribrosa by elevated intraocular pressure. Br. J. Ophthalmol. 1994, 78:643-648.
68. Yücel I., Akar Y., Yücel G., Ciftçioĝlu M.A., Keleş N., Aslan M. Effect of hypercholesterolemia on inducible nitric oxide synthase expression in a rat model of elevated intraocular pressure. Vision Res. 2005, 45:1107-1114.
69. Yücel I., Yücel G., Akar Y., Demir N., Gürbüz N., Aslan M. Transmission electron microscopy and autofluorescence findings in the cornea of diabetic rats treated with aminoguanidine. Can. J. Ophthalmol. 2006, 41:60-66.
70. Zhou L., Li Y., Yue B.Y. Oxidative stress affects cytoskeletal structure and cell-matrix interactions in cells from an ocular tissue: the trabecular meshwork. J. Cell Physiol. 1999, 180:182-189.